Application of rivaroxaban in patients with non-valvular atrial fibrillation and end-stage kidney disease: A systematic review and meta-analysis
- Resource Type
- article
- Authors
- Zhenzhen Yang; Jieya Wang; Ye Yuan; Tian Cheng; Feifei Ren; Songsong Wang; Zhiqing Zhang
- Source
- Frontiers in Cardiovascular Medicine, Vol 10 (2023)
- Subject
- rivaroxaban
non-valvular atrial fibrillation
end-stage kidney disease
systematic review
meta-analysis
Diseases of the circulatory (Cardiovascular) system
RC666-701
- Language
- English
- ISSN
- 2297-055X
BackgroundNowadays, the number of patients with non-valvular atrial fibrillation (NVAF) complicated by end-stage renal disease (ESKD) is increasing. There are significant challenges in anticoagulation with prescription drugs because of the high risk of bleeding and embolism among these patients. However, no randomized controlled trials (RCTs) of warfarin in combination with any non-vitamin K oral anticoagulant (NOACs) have been performed in patients with baseline creatinine clearance (CrCl)